{"title":"接受体外膜氧合的患者的健康资源利用和结果","authors":"Vicki Papanikolaou BBiomedSc, MPH , Ethan Goh BMedSc, MD , Alayna Carrandi BSc, MPH , Anaïs Charles-Nelson PhD , Kiran Kottakkal BMedSc, MD , Lorena Romero BA, MBIT , Carol L. Hodgson BAppSc(Physio), PGDip(Cardio), M(Research), PhD , Alisa M. Higgins BPhysio(Hons), GDipBiostat, MPH, PhD","doi":"10.1016/j.cjco.2025.03.019","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Extracorporeal membrane oxygenation (ECMO) is a high-cost, resource-intensive intervention for severe cardiac and respiratory failure. Survivors of ECMO have healthcare needs that extend beyond their acute hospitalization, placing significant demands on healthcare systems and society. As ECMO use increases globally, understanding the healthcare and economic burden of ECMO survivorship is needed to improve long-term outcomes of ECMO survivors and optimize resource allocation within healthcare systems.</div></div><div><h3>Methods</h3><div>We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Emcare, Scopus, and Web of Science from inception to October 1, 2024. We included studies published in English that reported post-discharge healthcare resource utilization and costs for adult survivors of ECMO.</div></div><div><h3>Results</h3><div>From 1889 articles screened, 24 studies met our inclusion criteria. Most were retrospective cohort studies conducted in North America between 2010 and 2024. Sample sizes ranged from 12 to 23,876 patients, with in-hospital mortality rates between 28.5% and 67.4%. Thirty-day readmission rates ranged from 10.0% to 43.8%, with 90-day rates ranging from 21.1% to 53.0%. One study reported a mean 30-day readmission cost of $62,150 (in 2023 US dollars). Only 5 studies (20.8%) reported total healthcare costs up to 6 months and 1 year.</div></div><div><h3>Conclusions</h3><div>ECMO survivorship is gaining increased attention in research and clinical practice, yet significant gaps remain in our understanding of long-term healthcare resource utilization and costs. Our review reveals very limited information, indicating an urgent need for more comprehensive and granular data to guide clinical and policy decisions and achieve healthcare system efficiency.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 6","pages":"Pages 750-758"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Health Resource Utilization and Outcomes Among Patients Who Receive Extracorporeal Membrane Oxygenation\",\"authors\":\"Vicki Papanikolaou BBiomedSc, MPH , Ethan Goh BMedSc, MD , Alayna Carrandi BSc, MPH , Anaïs Charles-Nelson PhD , Kiran Kottakkal BMedSc, MD , Lorena Romero BA, MBIT , Carol L. Hodgson BAppSc(Physio), PGDip(Cardio), M(Research), PhD , Alisa M. Higgins BPhysio(Hons), GDipBiostat, MPH, PhD\",\"doi\":\"10.1016/j.cjco.2025.03.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Extracorporeal membrane oxygenation (ECMO) is a high-cost, resource-intensive intervention for severe cardiac and respiratory failure. Survivors of ECMO have healthcare needs that extend beyond their acute hospitalization, placing significant demands on healthcare systems and society. As ECMO use increases globally, understanding the healthcare and economic burden of ECMO survivorship is needed to improve long-term outcomes of ECMO survivors and optimize resource allocation within healthcare systems.</div></div><div><h3>Methods</h3><div>We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Emcare, Scopus, and Web of Science from inception to October 1, 2024. We included studies published in English that reported post-discharge healthcare resource utilization and costs for adult survivors of ECMO.</div></div><div><h3>Results</h3><div>From 1889 articles screened, 24 studies met our inclusion criteria. Most were retrospective cohort studies conducted in North America between 2010 and 2024. Sample sizes ranged from 12 to 23,876 patients, with in-hospital mortality rates between 28.5% and 67.4%. Thirty-day readmission rates ranged from 10.0% to 43.8%, with 90-day rates ranging from 21.1% to 53.0%. One study reported a mean 30-day readmission cost of $62,150 (in 2023 US dollars). Only 5 studies (20.8%) reported total healthcare costs up to 6 months and 1 year.</div></div><div><h3>Conclusions</h3><div>ECMO survivorship is gaining increased attention in research and clinical practice, yet significant gaps remain in our understanding of long-term healthcare resource utilization and costs. Our review reveals very limited information, indicating an urgent need for more comprehensive and granular data to guide clinical and policy decisions and achieve healthcare system efficiency.</div></div>\",\"PeriodicalId\":36924,\"journal\":{\"name\":\"CJC Open\",\"volume\":\"7 6\",\"pages\":\"Pages 750-758\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CJC Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589790X25001787\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X25001787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
体外膜氧合(ECMO)是一种治疗严重心脏和呼吸衰竭的高成本、资源密集型干预手段。ECMO幸存者的医疗保健需求超出了他们的急性住院治疗,对医疗保健系统和社会提出了重大要求。随着ECMO使用在全球范围内的增加,需要了解ECMO幸存者的医疗保健和经济负担,以改善ECMO幸存者的长期预后并优化医疗系统内的资源分配。方法系统检索Ovid MEDLINE、Ovid Embase、Ovid Emcare、Scopus、Web of Science自成立至2024年10月1日。我们纳入了报道ECMO成年幸存者出院后医疗资源利用和成本的英文研究。结果在筛选的1889篇文章中,24项研究符合我们的纳入标准。大多数是2010年至2024年间在北美进行的回顾性队列研究。样本量从12例到23,876例不等,住院死亡率在28.5%到67.4%之间。30天的再入院率从10.0%到43.8%不等,90天的再入院率从21.1%到53.0%不等。一项研究报告称,平均30天的再入院费用为62,150美元(以2023年美元计算)。只有5项研究(20.8%)报告了长达6个月和1年的总医疗费用。结论在研究和临床实践中,肿瘤生存越来越受到重视,但我们对长期医疗资源利用和成本的认识仍存在重大差距。我们的回顾揭示了非常有限的信息,表明迫切需要更全面和更细致的数据来指导临床和政策决策,并实现医疗保健系统的效率。
Health Resource Utilization and Outcomes Among Patients Who Receive Extracorporeal Membrane Oxygenation
Background
Extracorporeal membrane oxygenation (ECMO) is a high-cost, resource-intensive intervention for severe cardiac and respiratory failure. Survivors of ECMO have healthcare needs that extend beyond their acute hospitalization, placing significant demands on healthcare systems and society. As ECMO use increases globally, understanding the healthcare and economic burden of ECMO survivorship is needed to improve long-term outcomes of ECMO survivors and optimize resource allocation within healthcare systems.
Methods
We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Emcare, Scopus, and Web of Science from inception to October 1, 2024. We included studies published in English that reported post-discharge healthcare resource utilization and costs for adult survivors of ECMO.
Results
From 1889 articles screened, 24 studies met our inclusion criteria. Most were retrospective cohort studies conducted in North America between 2010 and 2024. Sample sizes ranged from 12 to 23,876 patients, with in-hospital mortality rates between 28.5% and 67.4%. Thirty-day readmission rates ranged from 10.0% to 43.8%, with 90-day rates ranging from 21.1% to 53.0%. One study reported a mean 30-day readmission cost of $62,150 (in 2023 US dollars). Only 5 studies (20.8%) reported total healthcare costs up to 6 months and 1 year.
Conclusions
ECMO survivorship is gaining increased attention in research and clinical practice, yet significant gaps remain in our understanding of long-term healthcare resource utilization and costs. Our review reveals very limited information, indicating an urgent need for more comprehensive and granular data to guide clinical and policy decisions and achieve healthcare system efficiency.